The discontinuation of amcenestrant piles more pressure on the group’s chief executive, Paul Hudson.
Six months on from axing Epizyme’s PRMT-targeting projects GSK says no to Ideaya’s Mat2A work.
Early data in thyroid eye disease impress, but unanswered questions include the size of the market.
Novartis's latest failure, in adjuvant lung cancer, heaps more doubt on a rival approach from Cantargia.
As Zantac litigation risk wipes $43bn off public company valuations are investors right to be worried?